Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Georg Stüssi

12PUBLICATIONS

64CO-AUTHORS

Haematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Respiratory diseasesMedical molecular engineering of nucleic acids and proteins

Featured researcher

Get your video featured.

Publish with JoVE

Featured researcher

Get your video featured.

Publish with JoVE

Publications (12)

Sort by Publication Date:

|Mar 19, 2026

Flow Cytometry-Based Measurable Residual Disease Assessment in Patients With Acute Myeloid Leukemia Receiving Non-Intensive Chemotherapy.

Lukas H Haaksma, Tom Reuvekamp, Kasper J Croese

|Oct 07, 2025

Polatuzumab vedotin and CD79B: A study of efficacy in R-CHOP-resistant diffuse large B-cell lymphoma.

Nicolas Munz, Alberto J Arribas, Roberta Bordone Pittau

|Jul 14, 2025

IL-16 production is a mechanism of resistance to BTK inhibitors and R-CHOP in lymphomas.

Alberto J Arribas, Francesca Guidetti, Eleonora Cannas

|Feb 27, 2025

CD34+CD38- leukemia stem cells predict clinical outcomes in acute myeloid leukemia patients treated non-intensively with hypomethylating agents.

Tom Reuvekamp, Lok Lam Ngai, Daphne den Hartog

|Oct 07, 2024

PI3Kδ activation, IL-6 overexpression, and CD37 loss cause resistance to naratuximab emtansine in lymphomas.

Alberto J Arribas, Sara Napoli, Eugenio Gaudio

|Dec 05, 2023

ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms.

Alberto J Arribas, Sara Napoli, Luciano Cascione

Pageof 2

Frequent Collaborators

6 joint publications

Francesco Bertoni

5 joint publications

Chiara Tarantelli

5 joint publications

Alberto J Arribas

5 joint publications

Sara Napoli

5 joint publications

Luciano Cascione

4 joint publications

Andrea Rinaldi

4 joint publications

Emanuele Zucca

3 joint publications

Valter Gattei

3 joint publications

Filippo Spriano

3 joint publications

Manel Esteller

Frequent Collaborators

6 joint publications

Francesco Bertoni

5 joint publications

Chiara Tarantelli

5 joint publications

Alberto J Arribas

5 joint publications

Sara Napoli

Top Related Videos

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on : Oct 17, 2025

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [<sup>18</sup>F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [<sup>18</sup>F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on : Feb 17, 2022

<em>Ex vivo</em> Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation

<em>Ex vivo</em> Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation

Published on : Jan 14, 2011

See more related videos

Top Related Videos

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on : Oct 17, 2025

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [<sup>18</sup>F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [<sup>18</sup>F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on : Feb 17, 2022

<em>Ex vivo</em> Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation

<em>Ex vivo</em> Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation

Published on : Jan 14, 2011

See more related videos